Search

Displaying results 2671 - 2680 of 7706 in total
  1. Drug

    Salsalate

    go.drugbank.com/drugs/DB01399
    ApprovedInvestigational

    Salsalate's mode of action as an anti-inflammatory and antirheumatic agent may be due to inhibition of synthesis and release of prostaglandins. … Such capacity limited biotransformation results in an increase in the half-life of salicylic acid from 3.5 to 16 or more hours.

  2. Drug

    Viomycin

    go.drugbank.com/drugs/DB06827
    Approved

    Viomycin is a tuberactinomycin antibiotic that was used to treat Mycobacterium tuberculosis until it was replaced by the less toxic capreomycin. These drugs bind RNA in bacterial ribosomes and inhibit protein synthesis. Viomycin was deri...

  3. Drug

    Phenformin

    go.drugbank.com/drugs/DB00914
    ApprovedWithdrawn

    Although it is generally considered to be associated with an unacceptably high incidence of lactic acidosis, often fatal, it is still available in some countries.

  4. Drug

    Trofinetide

    go.drugbank.com/drugs/DB06045
    Approved

    [A258438] Trofinetide was approved by the FDA on March 10, 2023, for the treatment of Rett syndrome,[L45718,L45748] which is an X-linked neurodevelopmental disorder characterized by a range of cognitive

  5. Drug

    Octreotide

    go.drugbank.com/drugs/DB00104
    ApprovedInvestigational

    [L14501] In most cases, it results from an anterior pituitary growth hormone-releasing tumor. … On June 26, 2020, the first approved delayed-release oral somatostatin analog, Mycapssa, received FDA approval for the long term maintenance treatment of acromegaly.

  6. Drug

    Crinecerfont

    go.drugbank.com/drugs/DB18518
    ApprovedInvestigational

    [A264818] Crinecerfont was approved by the FDA in December 2024 as an adjunct to glucocorticoid replacement in patients with CAH.[L51973,L51993]

  7. Drug

    Lurbinectedin

    go.drugbank.com/drugs/DB12674
    ApprovedInvestigational

    [A214331] On June 15, 2020, the FDA granted accelerated approval and orphan drug designation to lurbinectedin for the treatment of adult patients with metastatic SCLC who have experienced disease progression … [A214310] It is a derivative of the marine-derived agent ecteinascidin ([trabectedin]), an anticancer agent found in extracts of the tunicate _Ecteinascidia turbinata_, with the primary difference being

  8. Drug

    Gadoquatrane

    go.drugbank.com/drugs/DB33282
    Approved

    [L63930] Bayer announced FDA approval of gadoquatrane on June 15, 2026, for use with MRI in adult and pediatric patients, including term neonates, to detect and visualize lesions with abnormal vascularity … [L63814] Its distinguishing feature is its tetrameric structure carrying four chelated gadolinium ions with high relaxivity, which allows an adequately enhanced examination to be obtained while delivering

  9. Drug

    Diethylpropion

    go.drugbank.com/drugs/DB00937
    ApprovedIllicitInvestigational

    A appetite depressant considered to produce less central nervous system disturbance than most drugs in this therapeutic category. It is also considered to be among the safest for patients with hypertension. (From AMA Drug Evaluations Ann...

  10. Drug

    Artemether

    go.drugbank.com/drugs/DB06697
    ApprovedInvestigational

    Artemether is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with lumefantrine for improved efficacy.